JPRN-jRCT2080221108UnknownPhase 1
Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate Treatment
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Eli Lilly Japan K.K.
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 75age old (—)
- Sex
- All
Inclusion Criteria
- •Eligible patients are those who have rheumatoid arthritis according to the American Rheumatism Association 1987 revised criteria, who have used methotrexate for at least 12 weeks and have been on a stable dose, at least 7.5 mg/week, for no less than 8 weeks. Serum C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) values must be more than the upper limit of normal (ULN) at study entry.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 1
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's DiseaseJPRN-jRCT2080223501Eli Lilly Japan K.K.
Active, not recruiting
Not Applicable
Single-Dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010821-38-GBElevation Pharmaceuticals, Inc12
Unknown
Phase 1
Multiple-Dose, Dose-Escalation Study to EvaluateRheumatoid ArthritisJPRN-jRCT2080221342Eli Lilly Japan K.K.
Completed
Phase 1
A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single and multi-dose regimePhase 1 drug studyNervous System DiseasesISRCTN98204977Alkermes (United States)147
Completed
Phase 1
K757 and K833 multiple-dose study in healthy subjectsHealthy subjectsISRCTN13328584Kallyope (United States)36